Malignant pleural mesothelioma

European Respiratory Journal

Volumn 12, Issue 4, 1998, Pages 972-981

  Boutin, C ^a,b   Schlesser, M ^a   Frenay, C ^a   Astoul, Ph ^a,b  

^a HÔPITAL DE LA CONCEPTION   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Asbestos; Cytokines; Malignant mesothelioma; Pleura; Thoracoscopy

Indexed keywords

ANTINEOPLASTIC AGENT; ASBESTOS; BLEOMYCIN; CISPLATIN; CYTOKINE; DOXORUBICIN; GAMMA INTERFERON; INTERLEUKIN 2; METHOTREXATE; MITOMYCIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; EARLY DIAGNOSIS; GENE THERAPY; HISTOLOGY; HUMAN; LYMPHOKINE ACTIVATED KILLER CELL; MULTIMODALITY CANCER THERAPY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; THORACOSCOPY; THORAX RADIOGRAPHY;

ASBESTOS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY; INCIDENCE; MALE; MESOTHELIOMA; PLEURAL NEOPLASMS; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 0031722628     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.98.12040972     Document Type: Article

References (113)

1. Eastwood EH, Martin JP. A case of primary tumour of the pleura. Lancet 1921; i: 172.
2. Wagner JC. Diffuse pleural mesothelioma and asbestos exposure in the North-West Cape Province. Br J Ind Med 1960; 17: 260-271.
3. Walker AM, Loughlin JE, Friedlander ER, Rothman KJ, Dreyer NA. Projections of asbestos-related disease 1980-2009. J Occup Med 1983; 25: 409-425.
4. Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet 1995; 345: 535-539.
5. McDonald AD, McDonald JC. Epidemiology of malignant mesothelioma. In: Antman K, Aisner J, eds. Asbestos-related Malignancy. Orlando, Grune and Stratton, 1987; pp. 31-55.
6. Rucsh VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A lung cancer study group trial. J Thorac Cardiovasc Surg 1991; 102: 1-9.
7. Brenner J, Sordillo PP, Magill GB, Golbey RB. Malignant mesothelioma of the pleura. Review of 123 patients. Cancer 1982; 49: 2431-2435.
8. Butchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: experience with 29 patients. Thorax 1976; 31: 15-24.
9. Law MR, Gregor A, Hodson ME, Bloom HJG, Turner-Warwick M. Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients. Thorax 1984; 39: 255-259.
10. Alberts AS, Falkson G, Goedhals L, Vorobiof DA, van der Merwe LA. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988; 6: 527-535.
11. Dimitrov NV, McMahon S. Presentation, diagnostic methods, staging and natural history of malignant mesothelioma. In: Antman K, Aisner J, eds. Asbestos-related Malignancy. Orlando, Grune and Stratton 1987; pp. 225-238.
12. International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 1995; 108: 1122-1128.
13. Rusch VW, Venkatraman E. The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1996; 111: 815-826.
14. Sugarbaker DJ, Heher EC, Lee TH, et al. Extrapleural pneumonectomy, chemotherapy and radiotherapy in the treatment of diffuse malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1991; 102: 10-15.
15. Boutin C, Nussbaum E, Monnet I, et al. Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 1994; 74: 2460-2467.
16. Chailleux E, Pioche D, Chopra S, et al. Epidémiologie du mésothéliome pleural malin dans la région de Nantes-Saint-Nazaire. Evolution 1956-1992. Rev Mal Respir 1995; 4: 353-357.
17. Churg A. Chrysotile, tremolite and malignant mesothelioma in man. Chest 1988; 93: 621-628.
18. Boutin C, Dumortier P, Rey F, Viallat JR, De Vuyst P. Black spots concentrate oncogenic asbestos fibers in the parietal pleura. Am J Respir Crit Care Med 1996; 153: 444-449.
19. INSERM. Effets sur la santé des principaux types d'exposition à l'amiante. Expertise collective INSERM. Paris, Edition INSERM, 1997; p. 434.
20. McDonald JC, McDonald AD. The epidemiology of mesothelioma in historical context. Eur Respir J 1996; 9: 1932-1942.
21. Rey F, Viallat JR, Boutin C, et al. Les mésothéliomes environnementaux en Corse du Nord-Est. Rev Mal Respir 1993; 10: 339-345.
22. Iwatsubo Y, Pairon JC, Archambault de Beaune C, Chammings S, Bignon J, Brochard P. Pleural mesothelioma: a descriptive analysis based on a case-control study and mortality data in Ile de France 1987-1990. Am J Ind Med 1994; 26: 77-88.
23. Spirtas R, Beebe GW, Connelly RR, et al. Recent trends in mesothelioma incidence in United States. Am J Ind Med 1986; 9: 397-407.
24. Connelly RR, Spirtas R, Myers MH, Fraumeni JF Jr. Demographic patterns for mesothelioma in the United States. J Natl Cancer Inst 1987; 78: 1053-1060.
25. Armstrong BK, Musk AW, Baker JE, et al. Epidemiology of malignant mesothelioma in Western Australia. Med J Aust 1984; 141: 86-88.
26. Hillerdal G. The pathogenesis of pleural plaques and pulmonary asbestosis: possibilities and impossibilities. Eur J Respir Dis 1980; 61: 129-135.
27. Ruffié P, Feld R, Minkin S, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 1989; 7: 1157-1168.
28. Meijers JMM, Planteydt HT, Slangen JJM, Swaen GMH, van Vliet C, Sturmans F. Trends and geographical patterns of pleural mesotheliomas in the Nederlands 1970-1987. Br J Ind Med 1990; 47: 778-781.
29. McDonald JC. Health implications of environmental exposure to asbestos. Environ Health Perspect 1995; 62: 316-328.
30. Goldberg P, Goldberg M, Marne MJ, Hirsch A, Tredaniel J. Incidence of pleural mesothelioma in New Caledonia. A 10-year survey (1978-1987). Arch Environ Health 1991; 46: 306-309.
31. McConnochie K, Simonato L, Mavrides P, Christofides P, Pooley FD, Wagner JC. Mesothelioma in Cyprus: the role of tremolite. Thorax 1987; 42: 342-347.
32. Sakellariou K, Malamou-Mitsi V, Haritou A, et al. Malignant pleural mesothelioma from non occupational asbestos exposure in Metsovo (north-west Greece): slow end of epidemic? Eur Respir J 1996; 9: 1206-1210.
33. Baris YI, Saracci R, Simonato L, Skidmore JW, Artvinli M. Malignant mesothelioma and radiological chest abnormalities in two villages in central Turkey. An epidemiological and environmental investigation. Lancet 1981; i: 984-987.
34. Hughes JM, Weill H. Asbestos exposure. Quantitative assessment of risk. Am Rev Respir Dis 1986; 133: 5-13.
35. Lilienfeld DE. Asbestos-associated pleural mesothelioma in school teachers: a discussion of four cases. Ann NY Acad Sci 1991; 643: 454-458.
36. Churg A, DePaoli L. Clearance of chrysotile asbestos from human lung. Exp Lung Res 1988; 14: 567-574.
37. Anttila S, Kadalainen A, Taikina-aho O, Kyyrönen P, Vainio H. Lung cancer in the lower lobe is associated with pulmonary asbestos fiber count and fiber size. Environ Health Perspect 1993; 101: 166-170.
38. De Vuyst P, Dumortier P, Moulin E, et al. Asbestos bodies in bronchoalveolar lavage reflect lung asbestos body concentration. Eur Respir J 1988; 1: 362-367.
39. Teschler H, Konietzko N, Schoenfeld B, Ramin C, Schraps T, Costabel U. Distribution of asbestos bodies in the human lung as determined by bronchoalveolar lavage. Am Rev Respir Dis 1993; 147: 1211-1215.
40. Roggli VL, Benning TL. Asbestos bodies in pulmonary hilar lymph nodes. Mod Pathol 1990; 3: 513-517.
41. Stanton MF, Layard M, Tegeris A, et al. Relation of particle dimension to carcinogenicity in amphibole asbestoses and other fibrous minerals. J Natl Cancer Inst 1981; 67: 965-975.
42. Pott F. Animal experiments on biological effects of mineral fibres. In: Wagner JC, ed. Biological Effects of Mineral Fibers. Lyon, IARC Scientific Publications, No. 30, 1980; pp. 261-269.
43. Goodglick LA, Kane AB. Cytotoxicity of long and short crocidolite asbestos fibers in vitro and in vivo. Cancer Res 1990; 50: 5153-5163.
44. Boutin C, Sebastien P, Janson X, Viallat JR. Métrologie des fibres minérales dans des biopsies thoracoscopiques pulmonaires et pleurales. Résultats préliminaires. Poumon-Coeur 1981; 37: 253-257.
45. Dodson RF, Williams MG, Corn CJ, Brollo A, Bianchi C. Asbestos content of lung tissue, lymph nodes, and pleural plaques from former shipyard workers. Am Rev Respir Dis 1990; 142: 843-847.
46. Kohyama N, Suzuki Y. Analysis of asbestos fibers in lung parenchyma, pleural plaques, and mesothelioma tissues of North American insulation workers. NY Acad Sci 1991; 643: 27-52.
47. Kanazawa K, Roe FJC, Yamamoto T. Milky spots (taches laiteuses) as structures which trap asbestos in mesothelial layers and their significance in the pathogenesis of mesothelial neoplasia. Int J Cancer 1979; 23: 858-865.
48. Wang NS. Morphological data of pleura. Normal conditions. In: Chretien J, Bignon J, Hirsch A, eds. The Pleura in Health and Disease. New York, Masson, 1983; pp. 10-24.
49. Fraire AE, Cooper S, Greeberg SD, Buffler P, Langston C. Mesothelioma of childhood. Cancer 1988; 62: 838-847.
50. Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: diagnosis. Cancer 1993; 72: 389-393.
51. Antman KH, Corson GM, Li FP, et al. Malignant mesothelioma following radiation exposure J Clin Oncol 1983; 1: 695-700.
52. Zeng L, Fleury-Feith J, Monnet I, Boutin C, Bignon J, Jaurand MC. Immunocytochemical characterization of cell lines from human malignant mesothelioma. Hum Pathol 1994; 25: 227-234.
53. Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest 1997; 111: 106-109.
54. Whitley NO. Computed tomography and malignant mesothelioma. In: Antman K, Aisner J, eds. Asbestos-related Malignancy. Orlando, Grune and Stratton, 1987; pp. 265-299.
55. Rusch VW, Gadwin JD, Shuman WP. The role of computed tomography scanning in the initial assessment and the follow-up of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1988; 96: 171-177.
56. Maasilta P, Vehmas T, Kivisaari L, Tammilehto L, Mattson K. Correlations between findings at computed tomography (CT) and at thoracoscopy/thoracotomy/autopsy in pleural mesothelioma. Eur Respir J 1991; 4: 952-954.
57. Patz EF Jr, Shaffer K, Piwnica-Worms DR, et al. Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability. Am J Roentgenol 1992; 159: 961-966.
58. Bittner RC, Felix R. Magnetic resonance (MR) imaging of the chest: state of the art. Eur Respir J 1998; 11: 1392-1404.
59. Boutin C, Rey F, Gouvernet J, Viallat JR, Astoul P, Ledoray V. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part II: Prognosis and staging. Cancer 1993; 72: 394-404.
60. Beauchamps HD, Kundra NK, Aranson R, Chong F, MacDonnell KF. The role of closed pleural needle biopsy in the diagnosis of malignant mesothelioma of the pleura. Chest 1992; 102: 1110-1112.
61. Galateau F, Letourneux M, Auriault ML, et al. Immunohistochemical diagnosis of pleural neoplasms. Eur Respir Rev 1993; 3: 33-37.
62. Doglioni C, Dei Tos AP, Laurino L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996; 20: 1037-1046.
63. Donna A, Betta PG, Chiodera P, et al. Newly marketed tissue markers for malignant mesothelioma imunoreactivity of rabbit AMAD-2 antiserum compared with monoclonal antibody HBME-1 and a review of the literature on so-called antimesothelioma antibodies. Hum Pathol 1997; 28: 929-937.
64. Motoyama T, Watanabe T, Okazaki E, Tanaka N, Watanabe H. Immunohistochemical properties of malignant mesothelioma cells in histologic and cytologic specimens. Acta Cytol 1995; 39: 164-170.
65. Boutin C, Viallat JR, Aelony Y. Practical thoracoscopy. Heidelberg, Springer. 1991; 1 Vol., p. 107.
66. Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. Chest 1995; 108: 754-758.
67. Antman KH, Shemin R, Ryan L, et al. Malignant mesothelioma: pronostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades 1965-1985. J Clin Oncol 1988; 6: 147-153.
68. Chahinian APH, Pajak TF, Holland JF, Norton L, Ambinder RM, Mandel EM. Diffuse malignant mesothelioma (prospective evaluation of 69 patients). Ann Intern Med 1982; 96: 746-755.
69. Chahinian AP. Therapeutic modalities in malignant pleural mesothelioma. In: Chrétien J, Hirsch A, eds. Diseases of the Pleura. New York, Masson, 1983; pp. 224-236.
70. Sugarbaker DJ, Strauss GM, Lynch TJ, et al. Node status has prognostic significance in the multimodality therapy of diffuse malignant mesothelioma. J Clin Oncol 1993; 11: 1172-1178.
71. Rusch VW, Saltz L, Venkatraman E, et al. A phase II trial of pleurectomy decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol 1994; 12: 1156-1163.
72. Sugarbaker DJ, Garcia JP, Richards WG, et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma: results in 120 consecutive patients. Ann Surg 1996; 288-296.
73. Antman KH. Clinical presentation and natural history of benign and malignant mesothelioma. Semin Oncol 1981; 8: 313-320.
74. Wörn H. Chances and results of surgery of malignant mesothelioma of the pleura. Thorax-Chirurgie 1974; 22: 391-393.
75. Probst G, Buelzebruck H, Bauer HG, Branscheid D, Vogt-Moykopf I. The role of pleuropneumonectomy in the treatment of diffuse malignant mesothelioma of the pleura. In: Deslauriers J, Lacquet LK, eds. Surgical Management of Pleural Diseases, Vol. 6. St. Louis CV Mosby Co. 1990; pp. 344-350.
76. Aisner J. Current approach to malignant mesothelioma of the pleura. Chest 1995; 107: 332S-344S.
77. Hakkinen AM, Laasonen A, Linnainmaa K, Mattson K, Pyrhönen S. Radiosensitivity of mesothelioma cell lines. Acta Oncol 1996; 35: 451-456.
78. Linden CJ, Mercke C, Albrechtsson U, Johansson L, Ewers SB. Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliorna: a non-randomized phase II study. Eur Respir J 1996; 9: 2565-2572.
79. Gordon W, Antman KH, Greenberger JS, Weichselbaum RR, Chaffey JT. Radiation therapy in the management of patients with mesotheliorna. Int J Rad Oncol Biol Phys 1982; 8: 19-25.
80. Ball DL, Cruickshank DG. The treatment of malignant mesothelioma of the pleura: review of a 5 year experience, with special reference to radiotherapy. Am J Clin Oncol 1990; 13: 4-9.
81. Low EM, Khoury GG, Matthews AW, Neville E. Prevention of tumour seeding following thoracoscopy in mesothelioma by prophylactic radiotherapy. Clin Oncol (R Coll Radiol) 1995; 7: 317-318.
82. Sorensen PG, Bach F, Bork E, Hansen HH. Randomized trial of doxorubicine versus cyclophosplamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep 1985; 69: 1431-1432.
83. Aisner J, Wiemik PH. Chemotherapy in the treatment of malignant mesothelioma. Semin Oncol 1981; 8: 335-343.
84. Ruffle P. Mesothelioma chemotherapy. Eur Respir Rev 1993; 3: 199-203.
85. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma: a review. J Clin Oncol 1996; 14: 1007-1017.
86. Zidar BL, Green S, Pierce HI, Roach RW, Balcerzak SP, Militello L. A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a South West oncology group study. Invest New Drugs 1988; 6: 223-226.
87. Planting AST, Schellens JHH, Goey SH, van-der-Burg ME, de-Boer-Dennert M. Weekly high-dose cisplatine in malignant mesothelioma. Ann Oncol 1994; 5: 373-374.
88. Solheim OP, Saeter G, Finnanger AM, Stenwig AE. High dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 1992; 6: 956-960.
89. Chahinian AP, Antman K, Goutsou M, et al. Randomized phase II trial of cisplatine with mytomycine or doxorubicine for malignant mesothelioma by the cancer and leukemia group B. J Clin Oncol 1993; 11: 1559-1565.
90. Breau JL, Boaziz C, Morère JF, Sadoun D, Israel L. Chemotherapy with cisplatin, adriamycin, bleomycin and mitomycin C, combined with systemic and intrapleural hyaluronidase in stage II and III mesothelioma. Eur Respir Rev 1993; 3: 223-225.
91. Dimitrov NV, Egner J, Balcueva E, Suhrland LG. High dose methotrexate with citroverum factor and vincristine in the treatment of malignant mesothelioma. Cancer 1982; 50: 1245-1247.
92. Kasseyet S, Boutin C, Astoul Ph, Sellier P, Nussbaum E. Chinliothèrapie du mésothéliome pleural malin (MPM). Résultats d'un essai de phase II d'une polychimiothérapie-PMFE. Rev Mal Res 1995; 12: R75.
93. Fitzpatrick DR, Manning LS, Musk AW, Robinson BW, Bielefeldt-Ohmann H. Potential for cytokine therapy of malignant mesothelioma. Cancer Treat Rev 1995; 21: 273-288.
94. Goey SH, Eggermont AM, Punt CJ, et al. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study. Br J Cancer 1995; 72: 1283-1288.
95. Ijzermans JNM, Marquet RL. Interferon gamma: a review. Immunobiology 1989; 179: 456-473.
96. Phan-Bich L, Buard A, Petit JF, et al. Differential responsiveness of human and rat mesothelioma cell lines to recombinant interferon gamma. Am J Respir Cell Mol Biol 1997; 16: 178-186.
97. Zeng L, Buard A, Monnet I, et al. In vitro effects of recombinant human interferon gamma on human mesothelioma cell lines. Int J Cancer 1993; 55: 515-520.
98. Mannel DN, Falk W. Interferon gamma is required in activation of macrophages for tumor cytotoxicity. Cell Immunol 1983; 79: 396-402.
99. Trinchieri G, Perussia B. Immune interferon: a pleiotropic lymphokine with multiple effects. Immunol Today 1985; 6: 131-133.
100. Weimar W, Bantje TA, Bron AO, Hilvering C, Bolhuis P, Schellekens H. Interferon therapy for pleural mesothelioma. In: De Maeyer E, Galasso G, Schellekens H, eds. The Biology of the Interferon System. Amsterdam, Elsevier/North Holland Biomedical Press, 1981; pp. 401-404.
101. Le J, Willcek J. Lymphokine-mediated activation of human monocytes: neutralisation by monoclonal antibody to interferon gamma. Cell Immunol 1984; 85: 278-283.
102. Nathan CF, Muray HM, Wiebe M, Rubin BY. Identification of interferon gamma as the lymphokine that activates human macrophages oxidative metabolism and antimicrobial activity. J Exp Med 1983; 158: 670-689.
103. Yasumoto K, Myazaki K, Nagashima A, et al. Induction of lymphokine-activated killer cells by intrapleural instillations of rIL-2 in patients with malignant pleurisy due to lung cancer. Cancer Res 1987; 44: 2184-2187.
104. Robinson BWS. Asbestos and cancer: human natural killer cell activity is suppressed by asbestos fibers but restored by rIL-2. Am Rev Respir Dis 1989; 139: 897-901.
105. Manning LS, Bowman RV, Darby SB, Robinson BS. Lysis of human malignant mesotheliorna cells by natural killer and lymphokine-activated killer cells. Am Rev Respir Dis 1989; 139: 1369-1374.
106. Astoul Ph, Bertault-Peres P, Durand A, Catalin J, Vignal F, Boutin C. Pharmacokinetics of intrapleural recombinant interleukin 2 in immunotherapy for malignant pleural effusion. Cancer 1994; 73: 308-313.
107. Astoul PH, Viallat JR, Laurent JC, Brandely M, Boutin C. Intapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion. Chest 1993; 103: 209-213.
108. Driesen P, Boutin C, Viallat JR, Astoul Ph, Vialette JP, Pasquier J. Implantable access system for prolonged intrapleural immunotherapy. Eur Respir J 1994; 7: 1989-1992.
109. Astoul Ph, Viallat J, Ledoray V, Boutin C. Interleukine-2 administrée par voie pleurale dans le traitement du mesotheliome pleural malin (Abstract). Rev Mal Respir 1996; 112: R103.
110. Kucharczuk JC, Elshami AA, Zhang HB, et al. Pleural-based mesothelioma in immune competent rats: a model to study adenoviral gene transfer. Ann Thorac Surg 1995; 60: 593-597.
111. Smythe WR, Hwang HQ Elshami AA, et al. Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann Surg 1995; 222: 78-86.
112. Antman KH, Blum RH, Greenberger JS, Flowerdew G, Skarin AT, Canellos GP. Multimodality therapy for malignant mesotheliorna based on a study of natural history. Am J Med 1980; 68: 356-362.
113. Viallat JR, Rey F, Astoul Ph, Boutin C. Thoracoscopic talc poudrage pleurodesis for malignant effusions: a review of 360 cases. Chest 1996; 110: 1387-1393.